Thiazolidinediones (TZDs: pioglitazone and rosiglitazone), which act as peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, are approved medications for type 2 diabetes, usually as second-line options [110]. Here, PPARG is linked to type 2 diabetes mellitus.